Journal
PHARMACOLOGY & THERAPEUTICS
Volume 172, Issue -, Pages 101-115Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2016.12.001
Keywords
AKT; PKB; PI3K/AKT signalling; AKT inhibitors; Cancer
Categories
Funding
- Cancer Research UK [C347/A18077]
- Experimental Cancer Medicine Centre [C12540/A15573]
- National Institute for Health Research Biomedical Research Centre
- Cancer Research UK [22897, 11566] Funding Source: researchfish
Ask authors/readers for more resources
PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a central component of the pathway, influencing multiple processes that are directly involved in tumourigenesis. Targeting ART is therefore a highly attractive anti-cancer strategy with multiple ART inhibitors now in various stages of clinical development. In this review, we summarise the role and regulation of AKT signalling in normal cellular physiology. We highlight the mechanisms by which AKT signalling can be hyperactivated in cancers and discuss the past, present and future clinical strategies for AKT inhibition in oncology. (C) 2016 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available